🧐 Semaglutide vs. Tirzepatide vs. Retatrutide: What’s the Difference?
Share
In the evolving world of metabolic and weight-related research, three compounds are leading the charge: Semaglutide, Tirzepatide, and Retatrutide. Each targets a unique combination of receptors—providing opportunities for exploring appetite, glucose, and energy regulation pathways. Here's how they compare.
🔹 Semaglutide — The Research Classic
Mechanism: GLP-1 receptor agonist — supports the study of appetite and glucose modulation.
- ~15% change in body weight reported in clinical trials
- Extensively documented and widely researched
- Often used in foundational metabolic studies
🔹 Tirzepatide — Dual-Agonist Performance
Mechanism: GLP-1 + GIP receptor agonist — dual activity for studying enhanced metabolic signaling.
- ~21% body weight change observed in trials
- Potential relevance for insulin and lipid metabolism research
- Often explored in mid-stage metabolic research designs
🔹 Retatrutide — The Triple Agonist
Mechanism: GLP-1 + GIP + Glucagon receptor agonist — offers a multi-receptor approach for metabolic and energy balance research.
- Up to 24.2% body weight change reported in early studies
- May support research into thermogenic pathways and liver lipid modulation
- Still in early-stage exploration; not FDA-approved
📊 Quick Comparison Chart
| Compound | Receptor Targets | Avg. Weight Change | Research Focus |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | Foundational studies |
| Tirzepatide | GLP-1 + GIP | ~21% | Dual-pathway exploration |
| Retatrutide | GLP-1 + GIP + Glucagon | Up to 24.2% | Advanced signaling models |
🔬 Why Researchers Choose NovaGene Labs
- Available in both pre-mixed and lyophilized formats
- Cold-chain shipping for maximum peptide stability
- Buy 2, Get 1 Free — auto-applied at checkout
- Trusted by thousands of research professionals nationwide
Disclaimer: All products sold by NovaGene Labs are intended strictly for Research Use Only. For more details, please visit our RUO policy: Read More →